

Complete Summary

GUIDELINE TITLE

Static lung volumes: 2001 revision and update.

BIBLIOGRAPHIC SOURCE(S)

Static lung volumes: 2001 Revision & Update. Respir Care 2001 May 1;46(5):531-39. [41 references]

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previously issued version (Static lung volumes. Respir Care 1994 Aug;39[8]:830-6).

COMPLETE SUMMARY CONTENT

SCOPE
 METHODOLOGY - including Rating Scheme and Cost Analysis
 RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS
 CONTRAINDICATIONS
 IMPLEMENTATION OF THE GUIDELINE
 INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT
 CATEGORIES
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

SCOPE

DISEASE/CONDITION(S)

Pulmonary disease

GUIDELINE CATEGORY

Evaluation
 Management

CLINICAL SPECIALTY

Family Practice
 Internal Medicine

INTENDED USERS

Respiratory Care Practitioners

GUIDELINE OBJECTIVE(S)

- To improve the consistency and appropriateness of respiratory care and serve as a guide for education and research.
- To provide clinical practice guidelines on measurement of static lung volumes and capacities in children (age ≥ 5) and adults.

TARGET POPULATION

Children (age ≥ 5) and adults with known or suspected impaired pulmonary function due to obstructive or restrictive disease processes with (but not limited to) the following indications:

- The need to diagnose restrictive disease patterns
- The need to differentiate between obstructive and restrictive disease patterns, particularly in the presence of a reduced vital capacity (VC)
- The need to assess response to therapeutic interventions (e.g., drugs, transplantation, radiation, chemotherapy, lobectomy, lung-volume-reduction surgery)
- The need to aid in the interpretation of other lung function tests (e.g., DL/VA, specific airway conductance [sG_{aw}], residual volume/total lung capacity [RV/TLC])
- The need to make preoperative assessments in patients with compromised lung function (known or suspected) when the surgical procedure is known to affect lung function
- The need to provide an index of gas trapping (by comparison of gas dilution techniques with plethysmographic measurements)

INTERVENTIONS AND PRACTICES CONSIDERED

Measurement of static lung volumes and capacities in children (age ≥ 5) and adults. The guideline focuses on commonly used techniques for measuring lung volumes, including spirometry, gas-dilution determination of functional residual capacity (FRC), and whole-body plethysmography determination of thoracic gas volume (TGV).

Other methods (e.g., single-breath nitrogen, single-breath helium, and roentgenologic determinations of lung volumes) are not discussed.

MAJOR OUTCOMES CONSIDERED

Outcome and test quality are determined by ascertaining that the desired information has been generated for the specific indication and that validity and reproducibility have been assured.

1. Results are valid if the equipment functions acceptably and the subject is able to perform the maneuvers in an acceptable and reproducible fashion.
2. Report of test results should contain a statement, by the technician performing the test, about test quality (including patient understanding of directions and effort expended) and, if appropriate, which recommendations were not met.

METHODOLOGY

METHODS USED TO COLLECT/SELECT EVIDENCE

Searches of Electronic Databases

DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

Not stated

NUMBER OF SOURCE DOCUMENTS

Not stated

METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Not stated

RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Not applicable

METHODS USED TO ANALYZE THE EVIDENCE

Systematic Review

DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Not applicable

METHODS USED TO FORMULATE THE RECOMMENDATIONS

Not stated

RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Not applicable

COST ANALYSIS

A formal cost analysis was not performed and published cost analyses were not reviewed.

METHOD OF GUIDELINE VALIDATION

External Peer Review

DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

Consultants to the Working Group may review the initial draft of the guideline. After completion by the Working group, the draft is reviewed by the entire Steering Committee and then by a Review Panel, persons engaged in all facets of the delivery of respiratory care who have volunteered to review drafts of the Guidelines before publication.

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

Description/Definitions:

- Static lung volumes are determined using methods in which airflow velocity does not play a role. The sum of two or more lung-volume subdivisions constitutes a lung capacity. The subdivisions and capacities are expressed in liters at body temperature and pressure saturated with water vapor (BTPS).
- Tidal volume (TV) is the volume of air that is inhaled or exhaled with each respiratory cycle. It varies with the conditions under which it is measured (e.g., rest, exercise, posture). When tidal volume is reported, an average of at least 6 breaths should be used.
- Inspiratory reserve volume (IRV) is the maximal volume of air that can be inhaled from tidal volume end-inspiratory level.
- Expiratory reserve volume (ERV) is the maximal volume of air that can be exhaled after a normal tidal exhalation (i.e., from functional residual capacity, or FRC).
- Residual volume (RV) is the volume of gas remaining in the lung at the end of a maximal expiration. It may be calculated by subtracting expiratory reserve volume from functional residual capacity (residual volume = functional residual capacity - expiratory reserve volume) or by subtracting vital capacity (VC) from total lung capacity, or TLC (residual volume = total lung capacity - vital capacity).
- Inspiratory capacity (IC) is the maximal volume of air that can be inhaled from the tidal-volume end-expiratory level (i.e., functional residual capacity). It is equal to the sum of tidal volume and inspiratory reserve volume.
- Vital capacity (VC) is the volume change that occurs between maximal inspiration and maximal expiration. The subdivisions of the vital capacity include tidal volume, inspiratory reserve volume, and expiratory reserve volume. The largest of three technically satisfactory vital capacity maneuvers should be reported. The two largest vital capacities should agree within 5% or 100 mL, whichever is larger. The volume change can be accomplished in several ways.

- Two-stage vital capacity: a slow maximal inspiration from tidal volume end-expiratory level after a normal exhaled tidal volume, followed by quiet breathing, followed by a slow maximal expiration from tidal volume (i.e., end-expiratory level, or functional residual capacity (i.e., FRC). The reverse maneuver is also acceptable;
- Forced vital capacity (FVC): the volume of air exhaled during a forced maximal expiration following a forced maximal inspiration. The FIVC is the forced vital capacity obtained during a maximal inspiration following a maximal expiration.
- Functional residual capacity is the volume of air in the lung at the average tidal volume end-expiratory level. It is the sum of the expiratory reserve volume and residual volume. When subdivisions of lung volume are reported, the method of measurement should be specified (e.g., helium dilution, nitrogen washout, body plethysmography).
- Thoracic gas volume (VTG) is the volume of air in the thorax at any point in time and at any level of thoracic expansion. It is usually measured by whole-body plethysmography. It may be determined at any level of lung inflation; however, it is most commonly determined at or near functional residual capacity. As an alternative, lung volume may be tracked continuously, and functional residual capacity determined from thoracic gas volume by addition or subtraction of volume.
- Total lung capacity (TLC) is the volume of air in the lung at the end of a maximal inspiration. It is usually calculated in one of two ways: (1) total lung capacity = residual volume + vital capacity or (2) total lung capacity = functional residual capacity + inspiratory capacity. The method of measurement (e.g., gas dilution, body plethysmography) should be specified.

Settings:

- Pulmonary function laboratories
- Cardiopulmonary laboratories
- Clinics and physicians' offices
- Patient care areas
- Study and field settings

Limitations of Methodology/Validation of Results:

- Patient-related limitations:
 - Slow vital capacity is effort-dependent and requires understanding and motivation on the subject's part. Physical and/or mental impairment may limit patient's ability to perform.
 - Some patients may be unable to perform the necessary panting maneuver required for plethysmographic determination of functional residual capacity.
 - Some subjects are unable to maintain mouth seal or cooperate adequately for the time necessary to perform the test. Cough is a common cause of such limitations.
 - Certain pathologic conditions in the subject can cause a leak in a lung-volume-measurement system (e.g., perforated eardrum, tracheostomy, transtracheal catheter, chest tube).
 - Functional residual capacity measured by gas dilution may be underestimated in individuals with airflow limitation and air trapping.

Body plethysmography may overestimate functional residual capacity in subjects with severe airway obstruction or induced bronchospasm at panting frequencies greater than 1 Hz (1 cycle/second).

- Elimination of nitrogen from tissues and blood can result in overestimation of the functional residual capacity in healthy subjects unless appropriate corrections are made.
- Test validation encompasses those calibration and procedural elements that help assure credible results:
 - Spirometry:
 - Spirometers (volume-displacement devices or flow-sensing devices) should meet the American (1994) and European Thoracic Societies' (1993) current accepted standards. Volume-displacement spirometers should be leak tested when calibrated (e.g., daily).
 - The vital capacity should be measured as close as possible in time to the functional residual capacity determination.
 - Gas-dilution methods for functional residual capacity determination:
 - Open-circuit multibreath nitrogen washout method:
 - Test should be continued for 7 minutes or until N₂ concentration falls below 1.0%. In subjects with airflow obstruction and air trapping, the time period for measuring functional residual capacity may need to be extended.
 - A minimum of 15 minutes should elapse before test is repeated.
 - Initial alveolar nitrogen concentration of 80% can be assumed if patient has been breathing room air for at least 15 minutes.
 - Closed-circuit multibreath helium equilibration method
 - The helium concentration should be measured at least every 15 seconds, and water vapor should be removed from the fraction of gas that is introduced into the helium analyzer. The reference cell of the He katharometer should also have a water absorber in-line, if room air is used for zeroing.
 - A mixing fan should circulate and completely mix the air throughout the main circuit.
 - The breathing valve and mouthpiece (without a filter) should add <60 mL dead space to the system for adults and a proportionately reduced increase for pediatric subjects and should be easy to disassemble for cleaning.
 - Gas mixing is considered complete when the change in helium concentration has been constant over a 2-minute period (i.e., changes less than 0.02%) or 10 minutes has elapsed. If the helium concentration can be read directly or processed by computer, helium equilibration can be assumed when the change is <0.02% in 30 seconds.
 - The need to correct for body absorption of helium is controversial.
 - The delay between the repeated measurements should be at least the same as the time taken to reach equilibrium or 5 minutes, whichever is greater.

- Whole body plethysmography
 - The frequency of panting breathing movements against the shutter should be 1 cycle/second.
 - The cheeks and chin should be firmly supported with both hands. This should be done without supporting the elbows or elevating the shoulders.
 - Plethysmographic determination of functional residual capacity is the method of choice in patients with airflow limitation and air trapping.
 - This method may be the more practical method in subjects with short attention spans or inability to stay on the mouthpiece (e.g., children).
- Reproducibility of results is essential to validation and test quality.
 - Multiple functional residual capacity determinations by gas dilution should be made, with at least two trials agreeing within 10% of the mean.
 - Functional residual capacity determinations by body plethysmography (at least 3 separate trials) should agree within 5% of the mean.
 - Inspiratory capacity and expiratory reserve volume measurements should agree within 5% or 60 mL (of the mean) whichever is larger. In patients who have large variability, this should be noted.
 - The two largest vital capacity measurements should agree within 200 mL.
- Clear and complete reporting of results is essential to test quality.
 - The average functional residual capacity value should always be reported (and should ideally include the variability).
 - The largest volume of either vital capacity or forced vital capacity should be reported
 - The largest reproducible value should be reported for inspiratory capacity and expiratory reserve volume.
 - Various methods are used for calculating total lung capacity and residual volume. The consensus of the Committee is that the two acceptable methods for reporting total lung capacity and residual volume from functional residual capacity determinations made using gas dilution techniques are:

Total lung capacity = mean functional residual capacity + largest inspiratory capacity,

Residual volume = total lung capacity - largest vital capacity; or

Residual volume = mean functional residual capacity - largest expiratory reserve volume,

Total lung capacity = residual volume + largest vital capacity.

For body plethysmographic determinations, a vital capacity maneuver (with its inspiratory capacity and expiratory reserve volume subdivisions) should be performed in conjunction with each thoracic gas volume maneuver and the total lung capacity calculated as:

Total lung capacity = functional residual capacity + inspiratory capacity.*

*(Note: the mean inspiratory capacity should be close to the largest inspiratory capacity) The reported total lung capacity should be the mean of all acceptable maneuvers; the residual volume should be calculated as:

Residual volume = mean total lung capacity - largest vital capacity.

- Conditions under which testing is done can affect results and should be controlled to the extent possible. If certain conditions cannot be met, the written report should reflect that:
 - Lung volumes are influenced by body position and should be made in the sitting position. If another position is used, it should be noted.
 - Breathing movements should not be restricted by clothing.
 - Diurnal variations in lung function may cause differences and, thus, if serial measurements are to be performed, the time of the day that measurements are made should be held constant.
 - The patient should not have smoked for at least 1 hour prior to the measurements.
 - The patient should not have had a large meal shortly before testing.
 - Nose clips should always be worn during testing.
 - Measurements made at ambient temperature and pressure saturated with water vapor (ATPS) conditions are corrected to body temperature and pressure saturated with water vapor (BTPS) conditions.
 - No corrections are necessary for altitude because no consistent differences in lung volumes (total lung capacity, vital capacity, functional residual capacity, and residual volume) due solely to altitude have been found from sea level up to 1,800 meters.
 - After the mouthpiece is in place, the patient should be asked to breathe quietly in order to become accustomed to the apparatus and attain a stable breathing pattern. The end-expiratory level should be reproducible within 100 mL.
 - Vital capacity can be measured before disconnecting the patient from measuring systems. As an alternative, the patient can be disconnected and the vital capacity performed immediately afterward.
 - If expired vital capacity is measured with a carbon dioxide absorber in the system, an appropriate volume correction must be made. (1.05 x expired volume is the correction commonly incorporated into commercial software.)
 - If a filter is used during functional residual capacity measurement, the filter volume must be subtracted.
- Choice of reference values may affect interpretation:
 - Make a tentative selection from published reference values. The characteristics of the healthy reference population should match the study group with respect to age, body size, gender, and race. The equipment, techniques, and measurement conditions should be similar.
 - Following selection of apparently appropriate reference values, compare measurements obtained from a representative sample of healthy individuals (10-20 subjects) over an appropriate age range to the predicted values obtained from the selected reference values. If an appreciable number of the sample falls outside of the normal range,

more appropriate reference values should be sought. This procedure detects only relatively gross differences between sample and reference population.

- Predicted values for residual volume, functional residual capacity, and total lung capacity should be derived from the same reference population.
- Expression of results:
 - The upper and lower limits of normal may be derived from the standard error of the estimates (SEE) around the regression lines. The two-tail 95% confidence interval can be estimated by multiplying $\pm 1.96 \times$ standard error of the estimates. A one-tailed 95% confidence interval can also be used for parameters in which only an abnormal high or low limit of normal is needed; the one-tailed limit is estimated by multiplying $\pm 1.64 \times$ standard error of the estimates and subtracting this value from the mean. These methods of estimating the limits of normal are applicable only if the reference data are normally distributed (Gaussian).
 - The common practice of expressing results as percent predicted and regarding 80% predicted as the lower limit of normal is not valid unless the standard deviation of the reference data is proportional to the mean value.

Assessment of Need (see the section titled "Indications" in the original guideline document)

Technologist-driven protocols may be useful for assessing the need for lung-volume determination, particularly in the context of other pulmonary function results (e.g., spirometry, diffusing capacity).

Assessment of Quality of Test and Validity of Results:

The consensus of the committee is that all diagnostic procedures should follow the quality model described in the NCCLS GP26-A A Quality System Model for Health Care (NCCLS, 940 West Valley Road, Ste. 1400, Wayne, PA 19087-1898; Web site: www.nccls.org). The document describes a laboratory path of workflow model that incorporates all the steps of the procedure. This process begins with patient assessment and the generation of a clinical indication for testing through the application of the test results to patient care. The quality system essentials defined for all health care services provide the framework for managing the path of workflow. A continuation of this model for respiratory care services is further described in NCCLS HS4-A A Quality System Model for Respiratory Care (NCCLS, 940 West Valley Road, Ste. 1400, Wayne, PA 19087-1898; Web site: www.nccls.org). In both quality models the patient is the central focus.

- General considerations include:
 - As part of any quality assurance program, indicators must be developed to monitor areas addressed in the path of workflow.
 - Each laboratory should standardize procedures and demonstrate intertechnologist reliability. Test results can be considered valid only if they are derived according to and conform to established laboratory quality control, quality assurance, and monitoring protocols.

- Documentation of results, therapeutic intervention (or lack of) and/or clinical decisions based on the testing should be placed in the patient's medical record.
- The type of medications, dose, and time taken prior to testing and the results of the pretest assessment should be documented.
- Report of test results should contain a statement by the technician performing the test regarding test quality (including patient understanding of directions and effort expended) and, if appropriate, which recommendations were not met.
- Test results should be interpreted by a physician, taking into consideration the clinical question to be answered.
- Personnel who do not meet annual competency requirements or whose competency is deemed unacceptable as documented in an occurrence report should not be allowed to participate, until they have received remedial instruction and have been re-evaluated.
- There must be evidence of active review of quality control, proficiency testing, and physician alert, or 'panic' values, on a level commensurate with the number of tests performed.
- Calibration measures specific to equipment used in measuring lung volumes include:
 - Spirometers and/or other volume transducers should be calibrated daily using a 3-L syringe or another more sophisticated device. Volume-based spirometers should be checked for leaks.
 - Gas dilution systems should have their gas analyzers, (i.e., He, N₂, O₂, CO₂) calibrated according to the manufacturer's recommendations immediately before each test. Some analyzers may require more frequent calibration.
 - Gas conditioning devices such as CO₂ and water absorbers should be inspected daily.
 - Body plethysmographs (including each transducer) should be calibrated at least daily, according to the manufacturer's recommendations. Leak checks or calculation of time constants should be performed in accordance with the manufacturer's recommendations.
- Quality control measures specific to measuring lung volumes include:
 - Lung volume analogs provide a means of checking the absolute accuracy and assessing precision. A 3-L syringe with/without an additional volume container can be used to check gas dilution systems (both open and closed circuit systems). As an alternative, a large-volume syringe can be used to assess the linearity of the associated gas analyzers, using a serial dilution technique.
 - Isothermal bottles can be constructed or purchased in order to check body plethysmograph function (volume accuracy).
 - Biologic controls should be used to assess the performance of the entire lung-volume system (transducers, gas analyzers, software). The means and standard deviations of 8-10 measurements of 2 or more healthy subjects may be used to check the precision of the system, as well as to troubleshoot when problems are suspected.

Resources:

- Equipment: Specifications should conform to recognized standards.

- All spirometers (volumetric or flow-based) should meet or exceed the minimum recommendations of the American Thoracic Society.
- Helium analyzers (katharometers) should be linear from 0 to 10% with a resolution less than 0.05% He and an accuracy of 0.1%. The gas flow through the meter should be constant at 20 mL/min or more. The 95% response time of the system (analyzer, spirometer with fan) for a 2% step change should be ≤ 15 seconds.
- Plethysmographs should include:
 - a patient compartment appropriate for the population to be tested;
 - a piston pump for box calibration and a manometer or similar device for mouth pressure calibration. A 3-liter syringe should be available for pneumotachometer calibration;
 - a vent to atmosphere (constant volume configurations);
 - a mouth shutter capable of closing within 0.1 seconds;
 - and an intercom for patient-technologist communication.
- Nitrogen analyzers should have a range of 0-100% \pm 0.5% with 50-millisecond response time or rapidly responding O₂ and CO₂ analyzers that allow calculation of the fraction of expired N₂ (F_{EN2}) should be incorporated.
- Personnel
 - Lung-volume testing should be performed under the direction of a physician trained in pulmonary diagnostics.
 - Personnel should be trained (with verifiable training and demonstrated competency) in all aspects of lung-volume determination, including equipment theory of operation, quality control, and test outcomes relative to diagnosis and/or medical history.
 - Attainment of either the Certified Pulmonary Function Technologist (CPFT) or Registered Pulmonary Function Technologist (RPFT) credential is recommended by the Committee.

Monitoring:

The following should be monitored during lung-volume determinations:

- reproducibility of repeated efforts;
- presence or absence of adverse effects of testing on the patient during testing. (Patients on supplemental oxygen may require periods of time to rest on oxygen between trials.)

Frequency:

The frequency of lung volume measurements depends on the clinical status of the subject and the indications for performing the test.

Infection Control:

- The staff, supervisors, and physician-directors associated with the pulmonary laboratory should be conversant with the "Guideline for Isolation Precautions in Hospitals" made by the Centers for Disease Control and Prevention and the Hospital Infection Control Practices Advisory Committee (HICPAC), and develop and implement policies and procedures for the laboratory that comply

- with its recommendations for "Standard Precautions" and "Transmission-Based Precautions."
- The laboratory's manager and its medical director should maintain communication and cooperation with the institution's infection control service and the personnel health service to help assure consistency and thoroughness in complying with the institution's policies related to immunizations, post-exposure prophylaxis, and job- and community-related illnesses and exposures.
 - Primary considerations include adequate handwashing, provision of prescribed ventilation with adequate air exchanges, careful handling and thorough cleaning and processing of equipment, and the exercise of particular care in scheduling and interfacing with the patient in whom a diagnosis has not been established. Considerations specific for lung-volume measurement include:
 - The use of filters is neither recommended nor discouraged. Filters may be appropriate for use in systems that use valves or manifolds on which deposition of expired aerosol nuclei is likely.
 - If filters are used in gas-dilution procedures, their volume should be subtracted when functional residual capacity is calculated.
 - If filters are used in the plethysmograph system, the resistance of the filters should be subtracted from the airways resistance calculation.
 - Nondisposable mouthpieces and equipment parts that come into contact with mucous membranes, saliva, and expirate should be cleaned and sterilized or subjected to high-level disinfection between patients. Gloves should be worn when handling potentially contaminated equipment.
 - Flow sensors, valves, and tubing not in direct contact with the patient should be routinely disinfected according to the hospital's infection control policy. Any equipment surface that displays visible condensation from expired gas should be disinfected or sterilized before it is reused.
 - Water-sealed spirometers should be drained weekly and allowed to dry.
 - Closed circuit spirometers, such as those used for He-dilution functional residual capacity determinations, should be flushed at least 5 times over their entire volume to facilitate clearance of droplet nuclei. Open circuit system need only have the portion of the circuit through which rebreathing occurs decontaminated between patients.

Age-Specific Issues:

Test instructions should be provided and techniques described in a manner that takes into consideration the learning ability and communications skills of the patient being served.

- Neonatal: This Guideline does not apply to the neonatal population.
- Pediatric: These procedures are appropriate for children who can perform spirometry of acceptable quality and can adequately follow directions for plethysmographic testing.
- Geriatric: These procedures are appropriate for members of the geriatric population who can perform spirometry of acceptable quality and adequately follow directions for plethysmographic testing.

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

Not specifically stated for each recommendation.

The guideline is developed from a thorough review of the literature, surveys of current practice, and the expertise of the members of the Working Group.

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

POTENTIAL BENEFITS

- Accurate measurement of static lung volumes and capabilities in children (age ≥ 5) and adults
- Appropriate utilization of techniques to measure lung volumes

POTENTIAL HARMS

Hazards/Complications:

- Infection may be contracted from improperly cleaned tubing, mouthpieces, manifolds, valves, and pneumotachometers.
- Hypoxemia may result from interruption of oxygen therapy in the body box.
- Ventilatory drive may be depressed in susceptible subjects (i.e., some carbon dioxide retainers) as a consequence of breathing 100% oxygen during the nitrogen washout. Such patients should be carefully observed.
- Hypercapnia and/or hypoxemia may occur during helium-dilution functional residual capacity determinations as a consequence of failure to adequately remove carbon dioxide or add oxygen to the rebreathed gas.

CONTRAINDICATIONS

CONTRAINDICATIONS

No apparent absolute contraindications exist; the relative contraindications for spirometry are appropriate and include the following:

- Hemoptysis of unknown origin;
- Untreated pneumothorax;
- Pneumothorax treated with a chest tube because the chest tube may introduce leaks and interfere with gas-dilution measurements;
- Unstable cardiovascular status; and
- Thoracic and abdominal or cerebral aneurysms.

With respect to whole-body plethysmography, such factors as claustrophobia, upper body paralysis, obtrusive body casts, intravenous pumps, or other conditions that immobilize or prevent the patient from fitting into or gaining access to the 'body box' are a concern. In addition, the procedure may necessitate stopping intravenous therapy or supplemental oxygen.

IMPLEMENTATION OF THE GUIDELINE

DESCRIPTION OF IMPLEMENTATION STRATEGY

An implementation strategy was not provided.

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

IOM CARE NEED

Living with Illness
Staying Healthy

IOM DOMAIN

Effectiveness
Safety

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

Static lung volumes: 2001 Revision & Update. Respir Care 2001 May 1;46(5):531-39. [41 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2001 May

GUIDELINE DEVELOPER(S)

American Association for Respiratory Care - Professional Association

SOURCE(S) OF FUNDING

American Association for Respiratory Care (AARC)

GUIDELINE COMMITTEE

Pulmonary Function Testing Clinical Practice Guidelines Committee

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Committee Members: Gregg Ruppel MD, RRT, RPFT; Susan Blonshine BS, RRT, RPFT; Catherine M Foss, BS, RRT, RPFT; Carl Mottram, BA, RRT, RPFT, Chair; Jack Wanger MS, RRT, RPFT

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previously issued version (Static lung volumes. Respir Care 1994 Aug;39[8]:830-6).

GUIDELINE AVAILABILITY

Electronic copies: Available from the [American Association for Respiratory Care \(AARC\) Web site](#).

Print copies: Available from AARC, CPG Desk, 11030 Ables Ln, Dallas, TX 75229-4593.

AVAILABILITY OF COMPANION DOCUMENTS

None available

PATIENT RESOURCES

None available

NGC STATUS

This summary was completed by ECRI on November 30, 1998. The information was verified by the guideline developer on December 15, 1998. This summary was updated by ECRI on August 24, 2001. The updated information was verified by the guideline developer as of October 17, 2001.

COPYRIGHT STATEMENT

Interested persons may copy the guidelines for noncommercial purposes of scientific or educational advancement. Please credit The American Association for Respiratory Care (AARC) and Respiratory Care Journal.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2006 National Guideline Clearinghouse

Date Modified: 9/25/2006

